Does low DHEA-S contribute to lower downstream testosterone availability in women?

In women, androgen physiology relies heavily on the adrenal glands, which provide the essential precursor hormones required for peripheral androgen synthesis. This assessment reviews how dehydroepiandrosterone sulfate (DHEA-S) serves as a marker of adrenal function and a critical substrate for downstream testosterone production.

Clinical evidence and markers of adrenal function

• Adrenal synthesis marker: DHEA-S is synthesized almost exclusively by the zona reticularis of the adrenal cortex. Because of its long half-life and stable circulating levels, serum DHEA-S is a highly specific, reliable clinical index of adrenal androgen synthetic capacity.
• Pathological vs. physiological decline: Low DHEA-S relative to age-matched reference ranges is a primary biomarker for central or primary adrenal insufficiency. It is also characteristic of ACTH-independent autonomous cortisol secretion (mild autonomous cortisol secretion), where cortisol feedback suppresses pituitary ACTH, subsequently shutting down adrenal androgen output.
• Age-related changes: In a 51-year-old female, clinical interpretation must account for the natural, progressive age-related decline in DHEA-S (adrenopause), as well as a physiological shift toward 11-oxygenated androgens which are not captured by standard DHEA-S assays.

Mechanistic pathway to downstream testosterone

• Sequential peripheral conversion: DHEA-S acts as an inactive circulating reservoir. In peripheral target tissues (including adipose tissue, liver, and skin), DHEA-S is desulfated to DHEA, converted to androstenedione, and subsequently synthesized into active testosterone.
• Substrate depletion: In women, approximately 50% of active circulating testosterone is derived from the peripheral conversion of adrenal precursors. Consequently, a depleted circulating DHEA-S pool directly limits the substrate available for these enzymatic conversions, contributing to lower downstream testosterone availability.
• Interventional validation: Clinical studies demonstrate that replenishing the precursor pool through oral DHEA supplementation in women with adrenal insufficiency or age-related decline reliably raises serum androstenedione and testosterone levels, confirming the functional dependency of downstream androgens on DHEA-S availability.

Bottom line

Low serum DHEA-S is a validated indicator of reduced adrenal androgen production. Because DHEA-S is the primary upstream precursor for peripheral androgen synthesis in women, a depleted DHEA-S pool directly restricts the substrate available for conversion, leading to lower downstream testosterone availability.